Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | FLT4 | P35916 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | STK3 | Q13188 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12108751 | 0.76 | KMT2A (0.66) | KMT2ACCR1CCR5CCR8PDK2 | |
| SCHEMBL6598757 | 0.76 | KMT2A (0.66) | KMT2ACCR1CCR5CCR8PDK2 | |
| SCHEMBL13151876 | 0.76 | KMT2A (0.71) | KMT2APIM1CCR1CCR5CCR8 | |
| SCHEMBL20672203 | 0.75 | NPSR1 (0.41) | KMT2ACDK5GSK3BPLK4PRKD3 | |
| SCHEMBL30029120 | 0.75 | NPSR1 (0.41) | KMT2ACDK5GSK3BPLK4PRKD3 | |
| SCHEMBL8661117 | 0.75 | PPOX (0.50) | KMT2ACDK5GSK3BPLK4PRKD3 | |
| SCHEMBL7485228 | 0.73 | KMT2A (0.49) | KMT2ACCR1CCR5CCR8ALDH1A1 | |
| SCHEMBL12191696 | 0.72 | ALDH1A1 (0.44) | KMT2ACDK5CCR1CCR5CCR8 | |
| SCHEMBL13544020 | 0.69 | TDP1 (0.56) | KMT2AGSK3BALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL13534041 | 0.69 | KMT2A (0.38) | KMT2ACDK5CCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020120143-A1 | Process for the preparation of 2,3-pyridinedicarboximides | INTELLECTUAL PROPERTY DEPARTMENT, BASF AKTIENGESELLSCHAFT (DE) | 2002-08-29 | — | — | US | disclosed |
| EP-0812842-B1 | Process for the preparation of 5-(alkoxymethyl)-2,3-pyridine-dicarboximide compounds | BASF AG (DE) | 2002-03-27 | — | — | EP | disclosed |
| EP-0812843-B1 | Process for the preparation of 2,3-pyridinedicarboximides | BASF AG (DE) | 2002-01-30 | — | — | EP | disclosed |
| US-6316629-B1 | AS CHEMICAL INTERMEDIATES TO OBTAIN HERBICIDES | AMERICAN CYANAMID CO. | 2001-11-13 | — | — | US | disclosed |
| US-6034253-A | CHEMICAL INTERMEDIATE FOR HERBICIDE | AMERICA CYANAMID COMPANY (US) | 2000-03-07 | — | — | US | disclosed |
| US-5905154-A | CHEMICAL CONDENSATION OF OXIME WITH HALOMALEIMIDE FOR HERBICIDES | AMERICAN CYANAMID COMPANY (US) | 1999-05-18 | — | — | US | disclosed |
| US-5849916-A | Process for the preparation of 2,3-pyridinedicarboximides | AMERICAN CYANAMID COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0812843-A2 | Process for the preparation of 2,3-pyridinedicarboximides | American Cyanamid Company (US) | 1997-12-17 | — | — | EP | disclosed |
| EP-0812842-A2 | Process for the preparation of 5-(alkoxymethyl)-2,3-pyridine-dicarboximide compounds | American Cyanamid Company (US) | 1997-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120143-A1 | Process for the preparation of 2,3-pyridinedicarboximides | PNPO, CHRNA9, NAPRT | KMT2A 1901/4885CDK5 829/4885GSK3B 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.